Nurse Practitioner, Family · Orlando, FL
NPI
1114569431
Since 2019
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
265 E Rollins St Ste 10000
Orlando, FL, 32804
Phone (407) 303-9921
Groups this clinician bills Medicare through
Medicare paid, 2024
$13K
159 services
Medicare patients, 2024
80
Average age 68
Drug cost, 2024
$16.7M
1,662 prescriptions
Company payments, 2025
$229K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Donna P Ortiz was code 99214 (office e&m - established), 118 times for 68 patients. In total Donna P Ortiz billed 159 services in 2 codes, and Medicare paid $13K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-09-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 118 | 68 | $78.82 | $9,301 |
| 99215 Office E&M - Established | Office | 41 | 35 | $96.61 | $3,961 |
By year: 2022 $15K for 188 services; 2023 $17K for 184 services; 2024 $13K for 159 services.
Medicare prescription drug claims, 2024
In 2024, the drug Donna P Ortiz prescribed most often to Medicare patients was Stelara (Ustekinumab), with 458 prescriptions and refills. In total Donna P Ortiz wrote 1,662 Medicare prescriptions that cost $16.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Stelara Ustekinumab | 458 | 544 | 56 | $12.7M |
| Rinvoq Upadacitinib | 103 | 105 | 17 | $701K |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 85 | 87 | 24 | $4,857 |
| Pantoprazole Sodium Generic | 68 | 184 | 24 | $1,166 |
| Omeprazole Generic | 68 | 188 | 26 | $957 |
| Humira(Cf) Pen Adalimumab | 60 | 61 | Under 11 | $792K |
| Colestipol Hcl Generic | 54 | 107 | 21 | $7,668 |
| Mesalamine Generic | 48 | 92 | 15 | $21K |
| Famotidine Generic | 47 | 114 | 18 | $956 |
| Dicyclomine Hcl Generic | 36 | 72 | 15 | $970 |
| Entyvio Vedolizumab | 32 | 42 | Under 11 | $272K |
| Skyrizi On-Body Risankizumab-Rzaa | 30 | 55 | Under 11 | $590K |
| Tramadol Hcl Generic | 23 | 23 | Under 11 | $156 |
| Ciprofloxacin Hcl Generic | 20 | 22 | Under 11 | $124 |
| Cimzia (2 Pack) Certolizumab Pegol | 20 | 20 | Under 11 | $158K |
Brand drugs: 951 claims; generic drugs: - claims; opioid claims: 23.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Donna P Ortiz $229K ($229K in general payments such as food, travel and fees) from 11 companies. The largest payer was Janssen Biotech, Inc. with $106K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 121 | $106K |
| Lilly USA, LLC LLY | 142 | $81K |
| Abbvie Inc. ABBV | 65 | $20K |
| Celltrion USA Inc. 068270.KS | 32 | $16K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 18 | $4,044 |
| Eli Lilly and Company LLY | 6 | $3,332 |
| Janssen Scientific Affairs, LLC JNJ | 1 | $37.91 |
| Pfizer Inc. PFE | 2 | $30.41 |
| Sandoz Inc. SDZ.SW | 1 | $24.55 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 1 | $24.4 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.